LGALS3 and obesity disorder: Recently, a wealth of human studies has provided evidence that galectin-3 levels are increased in subjects with obesity and type 2 diabetes, and animal studies have suggested that galectin-3 may be involved in the onset and progression of these metabolic disorders by acting primarily at the adipose tissue level.